TTrialPathMatch Me to Trials
← Back to trials
RecruitingVenous Thromboembolism (VTE)

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

Eligible age

18+ yrs

Accepts

All genders

Locations

11 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Sponsor: Regeneron Pharmaceuticals

Where it's recruiting

Alabama

Sheffield

California

Riverside

Colorado

Englewood

Florida

Delray Beach · Miami · Pensacola · Sarasota

Maryland

Baltimore

New Jersey

Westwood

Pennsylvania

Plymouth Meeting

Texas

Bellaire · Dallas · Houston · McAllen

Utah

St. George

Source: ClinicalTrials.gov · NCT07015905 · last updated 2026-07-13

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After T · TrialPath